# A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China

> **NCT05821855** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 120 (actual)

## Conditions studied

- Open-angle Glaucoma
- OAG

## Interventions

- **DEVICE:** XEN45 Glaucoma Treatment System
- **PROCEDURE:** Trabeculectomy

## Key facts

- **NCT ID:** NCT05821855
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-09
- **Primary completion:** 2030-07
- **Final completion:** 2030-07
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05821855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05821855, "A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05821855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*